Aspen Aerogels Inc. filed SEC Form 8-K: Other Events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. | Entry into a Material Definitive Agreement. |
On October 21, 2024, Aspen Aerogels, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 4,250,000 shares of the Company’s common stock, $0.00001 par value per share, to the Underwriters (the “Offering”). The price to the public in the Offering was $20.00 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 637,500 additional shares of common stock of the Company. The gross proceeds to the Company from the Offering are expected to be $85 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and excluding any exercise of the Underwriters’ option to purchase additional shares of common stock.
The Company intends to use the net proceeds of the Offering for working capital, capital expenditures and general corporate purposes.
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification and other obligations of the parties and termination provisions.
The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-282751), previously filed with the Securities and Exchange Commission (the “Commission”) on October 21, 2024, which became effective upon filing, and a related prospectus and prospectus supplement.
The Company expects to close the Offering on October 23, 2024, subject to the satisfaction of customary closing conditions.
The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and the foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to the legality of the issuance and sale of the shares in the Offering, is filed with this Current Report on Form 8-K as Exhibit 5.1, and incorporated herein by reference.
| Item 8.01. | Other Events |
On October 21, 2024, the Company issued a press release announcing pricing of the Offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
This Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, any securities referred to herein, nor will there be any sale of any such securities, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits: |
| Exhibit No. |
Description | |
| 1.1 | Underwriting Agreement, dated as of October 21, 2024, by and among Aspen Aerogels, Inc. and Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC. | |
| 5.1 | Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. | |
| 23.1 | Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1) | |
| 99.1 | Pricing Press Release, dated October 21, 2024 | |
| 104 | Cover Page Interactive Data File (Formatted as Inline XBRL) | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Aspen Aerogels, Inc. | ||||||
| Date: October 22, 2024 | By: | /s/ Ricardo C. Rodriguez | ||||
| Name: | Ricardo C. Rodriguez | |||||
| Title: | Chief Financial Officer and Treasurer | |||||
3